Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-06-30

Study Completion Date

2013-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research study is to determine if sorafenib improves the effectiveness of a procedure called radiofrequency ablation (RFA) for the treatment of hepatocellular cancer (HCC). Radiofrequency ablation has been used to treat many types of tumors, including hepatocellular cancers. During RFA a needle is inserted into the tumor tissue and heat is used to kill the tumor cells. Sorafenib has been approved by the FDA for the treatment of hepatocellular cancer that cannot be treated with surgery. Pre-clinical data suggests that sorafenib may improve the efficacy of RFA.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer

NCT01730937

Adult Primary Hepatocellular Carcinoma Advanced Adult Primary Liver Cancer Recurrent Adult Primary Liver Cancer

COMPLETED PHASE3

A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC)

NCT01801163

Hepatocellular Carcinoma

WITHDRAWN PHASE1

Sorafenib Tosylate in Treating Patients With Liver Cancer That Can Be Removed by Surgery

NCT01182272

Liver Cancer

UNKNOWN PHASE2

Radiofrequency Ablation in Treating Patients With Liver Cancer and Cirrhosis

NCT00132041

Liver Cancer

COMPLETED NA

Study of Combined Sorafenib With Radiotherapy in Patients With Advanced Hepatocellular Carcinoma

NCT01328223

Hepatocellular Carcinoma

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hepatocellular cancer (HCC) has a poor prognosis with increasing mortality in the United States. Because HCC generally develops in patients with underlying liver disease, resection is often not possible. Liver transplant improves survival for HCC patients but given the national organ donor shortage often patients have to wait a considerable time for transplant. Liver-directed therapies such as radiofrequency ablation (RFA) remain important tools to control tumor growth and to potentially "bridge" patients to liver transplant. However, liver-directed therapies for HCC tumors greater than 3cm in size are suboptimal, leaving a critical unmet need.

Antiangiogenic systemic agents, such as oral sorafenib, reduce tumor blood flow and have been shown to improve RFA efficacy in animal and in computer models.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatocellular Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sorafenib

Participants received a nine-day course of oral sorafenib 400 mg twice a day and radiofrequency ablation (RFA) on Day 10. Tumors in each group underwent RFA using a standard regimen (1 cm tip, 70 ± 2º C, 5 min).

Group Type EXPERIMENTAL

Sorafenib

Intervention Type DRUG

radiofrequency ablation

Intervention Type PROCEDURE

Placebo

Participants received a nine-day course of placebo pills twice a day and radiofrequency ablation (RFA) on Day 10. Tumors in each group underwent RFA using a standard regimen (1 cm tip, 70 ± 2º C, 5 min).

Group Type PLACEBO_COMPARATOR

radiofrequency ablation

Intervention Type PROCEDURE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sorafenib

Intervention Type DRUG

radiofrequency ablation

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Nexavar RFA

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed hepatocellular cancer (HCC) by pathology or by NCCN imaging guidelines
* All HCC stages are allowed. May be a liver transplant candidate.
* At least one tumor (index tumor) accurately measured as 3.5-7cm in diameter (long and short axis diameter to be recorded, but only one needs to meet this criteria) on baseline imaging.
* No prior therapy for the index tumor
* No prior systemic treatment for HCC within 4 weeks and no prior anti-VEGF therapy within 8 weeks of study entry.
* Life expectancy \> 8 weeks.
* ECOG \>=0 or 1
* RFA clinically indicated for index tumor.
* Acceptable overall RFA and anesthesia risk.
* Adequate bone marrow, liver and renal function: Hemoglobin \>9.0 g/dl; Absolute neutrophil count (ANC)\>1,500/mm3; Platelet count correctable to \>50,000/mm3; compensated liver function (Child-Turcotte-Pugh A, B7 or B8); Creatinine \<1.5 times ULN; INR correctable to \<1.5.
* Ability to take oral medication and no evidence of impaired absorption.

Exclusion Criteria

* Urgent treatment of the index tumor anticipated.
* Participants who have not recovered from adverse events due to agents administered more than 4 weeks earlier. Participants currently receiving any other study agents.
* Known brain metastases
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to sorafenib.
* Participants receiving medications or substances that are inducers of CYP3A4 (rifampicin, St. John's wort, phenytoin, carbamazepine, phenobarbital and dexamethasone) or that are metabolized/eliminated by predominantly UGT1A1 pathway or by CYP2B6 and CYP2C8.
* Decompensated liver disease
* Uncontrolled hypertension
* Thrombolic or embolic events within the past 6 months.
* Hemorrhage/bleeding event within 4 weeks
* Serious non-healing wound, ulcer, or bone fracture.
* Evidence of severe or uncorrectable bleeding diathesis or coagulopathy
* Major surgery, open biopsy or significant traumatic injury within 4 weeks of study entry.
* Contraindication to or inability to undergo the RFA procedure,
* Contraindication to or inability to undergo imaging with MRI
* Uncontrolled intercurrent illness
* Individuals with a history of a different malignancy unless disease-free for at least 5 years and are deemed by the Investigator to be at low risk for recurrence. Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.
* HIV-positive individuals on combination antiretroviral therapy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No